Funding Opportunities
The NIH Small Business Program is accepting applications for SBIR & STTR funding. Learn more about these open opportunities.
Learn how to apply and what to do if you encounter systems issues.
Next receipt date: Wednesday, April. 5, 2023
Five new Research Evaluation and Commercialization Hubs (REACH) have the chance to join NIH’s nationwide proof of concept network and receive $1 million per year for four years. Hubs will provide academic innovators with the initial investment to support product validation work and access to local and NIH product development experts to help them accelerate the translation of their scientific discoveries into products that improve health and save lives.
Learn more in the funding opportunity announcement (RFA-OD-23-005). Applications are due on Thursday, February 9, 2023, with projects expected to launch in December 2023.
The National Heart, Lung, and Blood Institute (NHLBI) Phase IIB Bridge (RFA-HL-23-009) and Small Market Award (RFA-HL-23-008) programs can provide up to $3 million over three years to continue the commercialization of novel products in the NHLBI mission space, specifically towards the completion of milestones necessary to achieve regulatory approval. This work must represent an extension of work completed under an SBIR Phase II award.
NIH support is particularly important for innovative products that have small markets. The National Center for Advancing Translational Sciences will consider co-funding awards in the small markets program (RFA-HL-23-008) that address rare diseases and platforms that address multiple rare diseases.
Applications to both programs will be accepted until Tuesday, February 28, 2023. For more information, contact nhlbi_sbir@mail.nih.gov.
The U.S. Food & Drug Administration (FDA) funds the Pediatric Device Consortia Grants Program to advance development, production, and distribution of pediatric medical devices. These nonprofit consortia provide a platform of experienced regulatory, business planning, and device development services such as intellectual property advising, prototyping, engineering, laboratory and animal testing, and grant-writing, to foster advancement of medical devices for pediatric patients. In addition to key advising services, the consortia also provide critical funding to innovators to directly advance these projects.
Learn more in the funding opportunity announcement (RFA-FD-23-024).
Applications are due by Wednesday, March 29, 2023.
Phase I grantees may be eligible for a free Technical and Business Assistance (TABA) Needs Assessment Report provided by RTI Innovation Advisors that gives a third-party, unbiased assessment of your project’s progress in four technical and business areas that are critical to success in the competitive healthcare marketplace:
- Market Needs/Competitive Advantage
- Intellectual Property/Barriers to Entry
- Business Model Profitability
- Manufacturing, Regulatory, and/or Clinical Plan
Your company is eligible to participate if your Phase I NIH SBIR or STTR (grant, contract, or Fast-Track):
- is active or was active within the past two years AND
- was not awarded TABA funding within the Phase I award budget AND
- has not already received a TABA Needs Assessment Report or NICHE Assessment for the same Phase I project.
TABA Needs Assessment Report requests are considered on a monthly basis to ensure companies receive timely guidance.
Learn more and submit a request to participate.
|
